- ¥6bn
- ¥1bn
- ¥8m
Annual cashflow statement for Noile-Immune Biotech, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Yuho | Yuho |
| Standards: | JAS | JAS | — | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -631 | -793 | -384 | -1,128 | -962 |
| Depreciation | |||||
| Non-Cash Items | 26.1 | 25.1 | 279 | 353 | -0.56 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 291 | -9.63 | -1.71 | -98.1 | 74.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -301 | -777 | -107 | -873 | -888 |
| Other Investing Cash Flow Items | — | -4.03 | — | -5.32 | 0.557 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | — | -4.03 | — | -5.32 | 0.557 |
| Financing Cash Flow Items | — | — | -12.5 | -595 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 996 | 2,374 | 488 | 1,913 | 2.5 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 696 | 1,592 | 380 | 1,035 | -885 |